The estimated Net Worth of John G Houston is at least $31.5 Milion dollars as of 23 February 2024. John Houston owns over 5,196 units of Arvinas Inc stock worth over $25,802,990 and over the last 6 years he sold ARVN stock worth over $244,472. In addition, he makes $5,485,840 as President, Chief Executive Officer a Director at Arvinas Inc.
John has made over 14 trades of the Arvinas Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,196 units of ARVN stock worth $244,472 on 23 February 2024.
The largest trade he's ever made was exercising 45,922 units of Arvinas Inc stock on 2 August 2021 worth over $734,752. On average, John trades about 12,190 units every 79 days since 2018. As of 23 February 2024 he still owns at least 1,036,681 units of Arvinas Inc stock.
You can see the complete history of John Houston stock trades at the bottom of the page.
Dr. John Houston Ph.D. is President, Chief Executive Officer, Director of the company. He has served as a member of our board of directors and as our President and Chief Executive Officer since September 2017. Dr. Houston served as our President of Research and Development and Chief Scientific Officer from January 2017 to September 2017 and has functioned as our principal executive officer since February 2017. Prior to joining Arvinas, Dr. Houston served as Senior Vice President of Specialty Discovery and R&D Site Evolution at Bristol Myers Squibb Company, a biopharmaceutical company, from September 2015 to August 2016, and as Senior Vice President Disease Sciences and Biologics from October 2010 to September 2015. Dr. Houston holds a Ph.D. in microbial biochemistry from Heriot-Watt University, Edinburgh and a B.Sc. in medical microbiology from the University of Glasgow. Houston is qualified to serve on our board due to his scientific and historical experience with us gained from serving as our President and Chief Executive Officer, combined with his previous scientific training and qualifications and the skills and experience he has developed during his extensive career in the life sciences industry.
As the President, Chief Executive Officer a Director of Arvinas Inc, the total compensation of John Houston at Arvinas Inc is $5,485,840. There are no executives at Arvinas Inc getting paid more.
John Houston is 60, he's been the President, Chief Executive Officer a Director of Arvinas Inc since 2017. There are 5 older and 13 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
John's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe a Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: